Radiofrequency ablation (RFA) is a minimally invasive therapy that has, until recently, received limited attention in the management of metastatic melanoma. RFA is well described in the management of primary malignancies of the liver, however limited data are available on its application to metastatic deposits of melanoma occurring in the lung, liver, or adrenal glands. This article explores the basic principles of RFA, its safety, efficacy, and application to metastatic malignancies of the lung, liver and adrenal glands, with particular emphasis on melanoma. Previously published results are reviewed, and we report a small additional series of patients with liver and lung metastases treated in Sydney using RFA.
No takes yet. Share an insight, caveat, or question.
Shashank et al. (2013) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: